Editas Medicine (EDIT) Notes Payables (2016 - 2017)
Editas Medicine (EDIT) reported Notes Payables of $7.5 million for Q4 2017, down 25.0% year-over-year from $10.0 million in Q4 2016, and down 50.0% on a QoQ basis from $15.0 million in Q2 2017.
Editas Medicine (EDIT) has 2 years of Notes Payables data on file, last reported at $7.5 million in Q4 2017.
- Quarterly Notes Payables fell 25.0% year-over-year to $7.5 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $7.5 million (down 25.0% YoY) and the FY2017 annual result came in at $7.5 million, down 25.0% from the prior year.
- Notes Payables fell to $7.5 million in Q4 2017 per EDIT's latest filing, from $15.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $15.0 million in Q1 2017 and bottomed at $7.5 million in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 7.50 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Mar 31, 2017 | 15.00 Mn |
| Dec 31, 2016 | 10.00 Mn |